RELATED STUDY

A CB2-Selective Cannabinoid Suppresses T-cell Activities and Increases Tregs and IL-10

Key Findings:  This study of the CB2-selective agonists O-1966, using Mixed Lymphocyte Reaction (MLR) on mice spleen cells as a model of transplant rejection, found that the compound effectively prevented or delayed graft rejection and presents a potential novel therapeutic target in graft-versus-host disease in transplant recipients.

Type of Study:  Laboratory Study

Study Result:  Positive

Study Location(s):  United States

Year of Pub:  2016


Cannabinoids Studied:  Tetrahydrocannabinol (THC), O-x Synthetic Cannabinoids, Endocannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  CB1, CB2

Ligands Studied:  Anti-inflammatory cytokines

Dosage: O-1966 (8 to 32 μM)

Route of Administration:  In vitro



Link to study